Kodiak Sciences Announces Sale of Future Royalties on KSI-301 for $225 Million to Baker Bros. Advisors
Kodiak Sells Capped Royalty Right on Global Net Sales of KSI-301 for $225 million Royalty Rate of 4.5% on Annual Net Sales Terminates after 4.5 times the Funded Amount Has Been Paid Transaction Enables an Immediate Acceleration of Clinical, Manufactu... Biopharmaceuticals, Ophthalmology, Venture Capital Kodiak Sciences, age-related macular degeneration
In today's open access research materials, the authors report that upregulation of the gene expression of an identified marker of aging, ELOVL2, can improve visual function in aging mice. Normally, expression of ELOVL2 declines with age, and consequent effects on visual function may involve the role of ELOVL2 in production of long-chain omega-3 and omega-6 polyunsaturated acids. These metabolites are in high demand in retinal cells, and lowered levels may well cause a sizable fraction of age-related dysfunction. Any discussion of this change in ELOVL2 expression and visual function is interesting in the context of w...
Background/Purpose: The role of blood malondialdehyde (MDA) in age-related macular degeneration (AMD), the leading cause of new blindness in industrialized countries, is still matter of debate. We performed a systematic review and meta-analysis of the published data on the MDA levels in AMD patients. Methods: PubMed, ISI Web of Sciences, and Scopus searches were performed according to MOOSE guidelines. Case–control studies were eligible for inclusion. Participants and controls were AMD patients and subjects without AMD, respectively. The main outcome measures were wet AMD and dry AMD. MDA level was the main expo...
Conclusion: When patients with CD are followed longitudinally, there was a significant risk of progression to GA or MNV for Phenotype 2 and Phenotype 3. Patients with CD are commonly first diagnosed in the fifth decade of life, and there is a female predominance. Clinicians should use multimodal imaging to detect and be aware of the risk of progression to manifestations of GA and MNV. These risks of GA and MNV suggest that patients with CD may be part of the overall spectrum of age-related macular degeneration.
Conclusion: This study suggests that some optical coherence tomography findings in eyes of patients with neovascular age-related macular degeneration were present before the start of anti–vascular endothelial growth factor therapy and may predict the development of MA.
Age-related macular degeneration (AMD) is a leading cause of blindness worldwide characterized by presence of drusen, leading to retinal pigment epithelium (RPE) and outer retinal changes in advanced stages. Approximately 10% of eyes with AMD develop neovascular complications and present with subretinal or sub-RPE exudation, hemorrhage, or both. Recent advances in imaging techniques, especially optical coherence tomography (OCT), help in early identification of disease and guide various treatment decisions; however, not all signs are suggestive of ongoing exudation or neovascular activity.
NANOTHERAPIES FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE: RECENT ADVANCEMENTS AND CHALLENGES. Recent Pat Drug Deliv Formul. 2020 Jan 16;: Authors: Rapalli VK, Gorantla S, Waghule T, Mahmood A, Singh PP, Dubey SK, Saha RN, Singhvi G Abstract Age-related Macular Degeneration (AMD) is one of the common diseases affecting the posterior part of the eye, affecting a large population above 45 years old. Anti-Vascular Endothelial Growth Factor-A (Anti-VEGF-A) agents have been considered as approved as therapeutic agents for the treatment of AMD. Due to the large molecular weight and po...
To investigate the features of neovascularization (NV) in eyes with neovascular age-related macular degeneration (NVAMD) using optical coherence tomography angiography (OCTA) according to the treatment interval of intravitreal aflibercept injection (IVI).
CONCLUSION: According to the studies included in this review, periodontal disease may be a plausible risk factor for AMD and may have a potential role in the earlier stages of this eye disease. Further studies should be encouraged for better understanding of this potential new relationship. PMID: 31926570 [PubMed - in process]
The program, facilitated by Johnson &Johnson Innovation, has the potential to improve the treatment of patients with retinal vascular diseases and transform the lives of those suffering from vision loss. CAMBRIDGE, England, Jan. 13, 2020 -- (Healthcare... Biopharmaceuticals, Ophthalmology Exonate, Janssen Pharmaceuticals, Johnson &Johnson, macular degeneration